FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091001837> ?p ?o ?g. }

• W2091001837 abstract "Article Abstract Context: Bipolar spectrum and treatment-resistant unipolar mood disorders are increasingly identified in primary care settings. Olanzapine demonstrates efficacy in the treatment of acute mania and bipolar depression and in bipolar maintenance therapy. Olanzapine-fluoxetine combination therapy shows efficacy in treatment-resistant depression. Objective: To examine the efficacy and tolerability profile of olanzapine in various difficult-to-treat depressive and/or anxious states in primary care outpatients. Method: A retrospective chart review was conducted for all identifiable patients prescribed olanzapine for mood disorders (DSM-IV) during a 3-year period (July 1998-July 2001), utilizing clinician and nurse recall, sampling of general continuity clinic records, and a hand search of mood disorder clinic records. Main and Secondary Outcome Measures: Initial and final scores on the Global Assessment of Functioning (GAF) scale, duration of therapy, and adverse effects. Results: Thirty-seven patients were identified as having received treatment with olanzapine; 3 were referred to the mental health specialty sector at the time of treatment initiation, and 2 were lost to follow-up. Of the 32 patients receiving ongoing treatment by primary care clinicians, most were female (N = 23; 72%) and all were white (100%). Most were diagnosed with a mental illness in the bipolar spectrum (N = 25; 78%) and demonstrated treatment resistance with antidepressants and/or mood stabilizers (mean number of previous psychotropic medications = 3.7). In the group completing therapy (24 patients ; mean duration of treatment = 242 days), GAF scores demonstrated a clinically and statistically significant improvement (mean initial GAF score = 59 ± 9; mean final GAF score = 76 ± 11; p < .0001).Twenty (83%) of these 24 patients demonstrated sustained improvement in their GAF scores. In the group that discontinued therapy (8 patients ; mean duration of treatment = 123 days), GAF scores also demonstrated a clinically and statistically significant improvement (mean initial GAF score = 51 ± 15; mean final GAF score = 70 ± 11; p < .0001). Six (75%) of these 8 patients demonstrated sustained improvement in their GAF scores. For all patients, observed adverse effects included weight gain (25 patients ; mean = 3.63 kg), sedation (6 patients ), and dry mouth (1 patient ). Conclusion: Olanzapine shows promise as an effective pharmacotherapeutic agent for primary care patients with mood disorders that lie along the bipolar spectrum or that are resistant to treatment with antidepressant monotherapies, but is associated with mild-to-moderate weight gain." @default.
• W2091001837 created "2016-06-24" @default.
• W2091001837 creator A5020526627 @default.
• W2091001837 creator A5044106829 @default.
• W2091001837 creator A5070880677 @default.
• W2091001837 creator A5087310161 @default.
• W2091001837 date "2004-10-15" @default.
• W2091001837 modified "2023-09-30" @default.
• W2091001837 title "Retrospective Study of Olanzapine in Depressive and Anxious States in Primary Care" @default.
• W2091001837 cites W155120211 @default.
• W2091001837 cites W1983662592 @default.
• W2091001837 cites W2022496892 @default.
• W2091001837 cites W2036861241 @default.
• W2091001837 cites W2037068562 @default.
• W2091001837 cites W2044128212 @default.
• W2091001837 cites W2074339845 @default.
• W2091001837 cites W2077630328 @default.
• W2091001837 cites W2082287891 @default.
• W2091001837 cites W2087695137 @default.
• W2091001837 cites W2111105929 @default.
• W2091001837 cites W2111355579 @default.
• W2091001837 cites W2114693958 @default.
• W2091001837 cites W2121339106 @default.
• W2091001837 cites W2135399947 @default.
• W2091001837 cites W2158954031 @default.
• W2091001837 cites W2172206754 @default.
• W2091001837 cites W2222352165 @default.
• W2091001837 doi "https://doi.org/10.4088/pcc.v06n0504" @default.
• W2091001837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/518985" @default.
• W2091001837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15514689" @default.
• W2091001837 hasPublicationYear "2004" @default.
• W2091001837 type Work @default.
• W2091001837 sameAs 2091001837 @default.
• W2091001837 citedByCount "3" @default.
• W2091001837 countsByYear W20910018372016 @default.
• W2091001837 countsByYear W20910018372017 @default.
• W2091001837 countsByYear W20910018372019 @default.
• W2091001837 crossrefType "journal-article" @default.
• W2091001837 hasAuthorship W2091001837A5020526627 @default.
• W2091001837 hasAuthorship W2091001837A5044106829 @default.
• W2091001837 hasAuthorship W2091001837A5070880677 @default.
• W2091001837 hasAuthorship W2091001837A5087310161 @default.
• W2091001837 hasBestOaLocation W20910018372 @default.
• W2091001837 hasConcept C118552586 @default.
• W2091001837 hasConcept C126322002 @default.
• W2091001837 hasConcept C139719470 @default.
• W2091001837 hasConcept C151730666 @default.
• W2091001837 hasConcept C162324750 @default.
• W2091001837 hasConcept C197934379 @default.
• W2091001837 hasConcept C2776174506 @default.
• W2091001837 hasConcept C2776412080 @default.
• W2091001837 hasConcept C2776619155 @default.
• W2091001837 hasConcept C2776809841 @default.
• W2091001837 hasConcept C2776867660 @default.
• W2091001837 hasConcept C2778375690 @default.
• W2091001837 hasConcept C2779343474 @default.
• W2091001837 hasConcept C2780200951 @default.
• W2091001837 hasConcept C2780550438 @default.
• W2091001837 hasConcept C2780733359 @default.
• W2091001837 hasConcept C71924100 @default.
• W2091001837 hasConcept C86803240 @default.
• W2091001837 hasConceptScore W2091001837C118552586 @default.
• W2091001837 hasConceptScore W2091001837C126322002 @default.
• W2091001837 hasConceptScore W2091001837C139719470 @default.
• W2091001837 hasConceptScore W2091001837C151730666 @default.
• W2091001837 hasConceptScore W2091001837C162324750 @default.
• W2091001837 hasConceptScore W2091001837C197934379 @default.
• W2091001837 hasConceptScore W2091001837C2776174506 @default.
• W2091001837 hasConceptScore W2091001837C2776412080 @default.
• W2091001837 hasConceptScore W2091001837C2776619155 @default.
• W2091001837 hasConceptScore W2091001837C2776809841 @default.
• W2091001837 hasConceptScore W2091001837C2776867660 @default.
• W2091001837 hasConceptScore W2091001837C2778375690 @default.
• W2091001837 hasConceptScore W2091001837C2779343474 @default.
• W2091001837 hasConceptScore W2091001837C2780200951 @default.
• W2091001837 hasConceptScore W2091001837C2780550438 @default.
• W2091001837 hasConceptScore W2091001837C2780733359 @default.
• W2091001837 hasConceptScore W2091001837C71924100 @default.
• W2091001837 hasConceptScore W2091001837C86803240 @default.
• W2091001837 hasIssue "5" @default.
• W2091001837 hasLocation W20910018371 @default.
• W2091001837 hasLocation W20910018372 @default.
• W2091001837 hasLocation W20910018373 @default.
• W2091001837 hasLocation W20910018374 @default.
• W2091001837 hasOpenAccess W2091001837 @default.
• W2091001837 hasPrimaryLocation W20910018371 @default.
• W2091001837 hasRelatedWork W1420655596 @default.
• W2091001837 hasRelatedWork W2001181945 @default.
• W2091001837 hasRelatedWork W2017951033 @default.
• W2091001837 hasRelatedWork W2057593928 @default.
• W2091001837 hasRelatedWork W2072567367 @default.
• W2091001837 hasRelatedWork W2077914434 @default.
• W2091001837 hasRelatedWork W2116167153 @default.
• W2091001837 hasRelatedWork W2123457703 @default.
• W2091001837 hasRelatedWork W2145186334 @default.
• W2091001837 hasRelatedWork W2379368698 @default.
• W2091001837 hasVolume "6" @default.
• W2091001837 isParatext "false" @default.
• W2091001837 isRetracted "false" @default.
• W2091001837 magId "2091001837" @default.

• next